000			02711na a2200277 4500
003			PC2922
005			20180417114300.0
008			130622s2003 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCastellano, Daniel _9882 _eOncología Médica
100			_aHitt Sabag, Ricardo _91474 _eOncología Médica
100			_aCiruelos Gil, Eva María _91082 _eOncología Médica
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
100			_aHitt Sabag, Ricardo _91474 _eOncología Médica
100			_aColomer, R. _91475 _eOncología Médica
245	0	0	_aBiweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors _h[artículo]
260			_c2003. _bAnnals of Oncology,
300			_a14(5):783-787
500			_aFormato Vancouver: Castellano D, Hitt R, Ciruelos E, Cortés-Funes H, Colomer R. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003 May;14(5):783-7.
501			_aContiene 27 referencias
520			_aBackground: The purpose of this study was to determine the dose-limiting toxicity (DLT) and maximum tolerated dose of a combination of vinorelbine plus gemcitabine administered on a biweekly schedule in patients with advanced solid tumors. Patients and methods: Patients with advanced or refractory solid tumors included in this phase I study were treated with vinorelbine followed by gemcitabine. Vinorelbine was given intravenously over 10 min, and gemcitabine was given intravenously at an fixed-dose infusion rate of 10 mg/m(2)/min. Six dose levels of vinorelbine/gemcitabine were explored: 20/2000, 25/2500, 25/3000, 30/3000, 30/3500 and 30/2500 mg/m(2). Results: Nineteen patients were included in the study. Fourteen patients were pretreated with chemotherapy and/or radiotherapy. A total of 123 cycles of chemotherapy were administered. DLTs were neutropenic fever and grade 3 asthenia at dose level 5 (30/3500 mg/m(2)); at dose level 4 (30/3000 mg/m(2)) they were grade 3 asthenia, and a radiation-recall reaction and pneumonitis. Sixteen patients were evaluable for efficacy. Five patients had an objective response (one complete response and four partial responses), for an overall response rate of 31%. Conclusions: The recommended dose for phase II study is vinorelbine 30 mg/m(2) and gemcitabine 2500 mg/m(2) administered once every 2 weeks. This regimen is feasible and well-tolerated at this dose, and shows a good clinical activity in all levels explored.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc2922.pdf _ySolicitar documento
942			_2ddc _cART _n0
999			_c2922 _d2922